Jan 15 (Reuters) - Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 ...
We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will ...
Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between ...
Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...
Boston Scientific paid $189 million for the recently completed Arbor Lakes campus in Maple Grove and already has big plans to ...
Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...
Medical Device Network on MSN
Boston Scientific touts long-term data of SCS therapy
At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.
This week's Medtech in a Minute features news about Boston Scientific and a potentially dangerous chemical used in IV bags ...
The Axios stent system is designed for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic ...
Boston Scientific said it will pay $374 a share in cash and stock for Penumbra, which makes products to remove blood clots ...
Boston Scientific stock snapshot after recent moves Boston Scientific (BSX) has seen mixed returns recently, with the share ...
With the planned purchase, Boston Scientific will gain several thrombectomy devices to remove clots from blood vessels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results